UCB (OTCMKTS:UCBJF) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• UCB shares experienced a significant increase in trading volume, with 15,184 shares traded, marking a 1,519% rise compared to the previous day.
• Morgan Stanley has upgraded UCB shares to an "overweight" rating, indicating expected growth potential in the company's stock performance.
• The stock closed at $227.63 after previously closing at $222.29, reflecting a 2.4% increase in value.

Shares of UCB SA (OTCMKTS:UCBJF - Get Free Report) saw unusually-high trading volume on Friday . Approximately 15,184 shares changed hands during trading, an increase of 1,519% from the previous session's volume of 938 shares.The stock last traded at $227.63 and had previously closed at $222.29.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of UCB to an "overweight" rating in a research note on Monday, June 23rd. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, UCB presently has an average rating of "Buy".

UCB Stock Performance

The business's 50-day moving average is $207.91 and its two-hundred day moving average is $187.28. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.